Sanofi expanding Fabrazyme plant in MA

By Dan Stanton contact

- Last updated on GMT

Sanofi Genzyme's facility in Framingham, MA. Image c/o Sanofi
Sanofi Genzyme's facility in Framingham, MA. Image c/o Sanofi

Related tags: Therapy

Sanofi will expand its Framingham, Massachusetts biomanufacturing facility by 14,820 square-foot to support its product portfolio.

Sanofi Genzyme confirmed the capacity increase at the site to Biopharma-Reporter after the news was broken by a local business journal.

“We are expanding our manufacturing production capacity in Framingham, in support of our portfolio and pipeline therapies with a 14,820 square-foot addition to a new building on our campus,”​ spokesperson Nicolas Kressman said.

Details regarding the size of investment and the hiring of staff were not divulged.

The facility was approved and opened in 2012​ in order to support Sanofi’s Fabry disease treatment Fabrazyme (agalsidase beta), freeing up capacity and cutting bottlenecks at Sanofi’s nearby Allston Landing site.

Fabrazyme is an enzyme replacement therapy first approved in 2003 in order to treat the inherited disorder Fabry Disease - a deficiency of the enzyme alpha galactosidase A - and costs approximately $200,000 per year​​.

Allston Landing was at one time running at production level of 30% of the demand​​ for the drug, leading to severe shortages and a petition by patients​​ to force Genzyme to break the drug’s patent

In 2013​, Sanofi said the Framingham site had solved the supply issues, and announced a further $80m investment in a new downstream plant in preparation  for anticipated growth in demand for the drug.

Related news

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Follow us


View more